Pharmaceutical Treatment of People with Dementia during the SARS-CoV-2 Pandemic in Germany: Polypharmacy, Anticholinergic Medication, and Antidementia Medication.

ABSTRACT:

Introduction

Dementia patients are at increased risk of polypharmacy and inappropriate medication, exacerbating cognitive decline. The SARS-CoV-2 pandemic constrained access to medical care and monitoring services for dementia patients, potentially worsening medication-related issues. We analyzed the medical treatment of dementia patients during the SARS-CoV-2 pandemic in Bavaria, particularly regarding polypharmacy, anticholinergic medication, and antidementia medication.

Methods

The Bavarian Ambulatory COVID-19 Monitor (BaCoM) is a longitudinal registry study conducted in Bavaria, Germany. Participants in need of nursing care with baseline data during the SARS-CoV-2 pandemic were included in our detailed analysis (N = 345, dementia sample n = 96 with a dement

SUBMITTER: Scheel-Barteit J 

PROVIDER: S-EPMC12503483 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature